

**Registration Number 4028374**  
**England and Wales**

**Biotech-IgG (UK) Limited**

**Abbreviated Accounts**

**For the year ended**

**31st December 2009**

WEDNESDAY



\*A2YOMNT0\*

A04

29/09/2010

320

COMPANIES HOUSE

# **Biotech-IgG (UK) Limited**

## **Financial statements for the year ended 31st December 2009**

---

### ***Contents***

### ***Pages***

Balance sheet

1-2

Notes to the financial statements

3-4

# Biotech-IgG (UK) Limited

Abbreviated balance sheet as at 31st December 2009

Registered Number 4028374

	<u>Notes</u>	<u>2009</u> <u>£</u>	<u>2008</u> <u>£</u>
<b>Fixed assets</b>			
Tangible assets	2	82	96
<b>Current assets</b>			
Debtors		20,911	21,264
Cash at bank and in hand		5,004	19,362
		25,915	40,626
<b>Creditors</b> amounts falling due within one year		(81,241)	(17,849)
<b>Net current liabilities(2008 assets)</b>		(55,326)	22,777
<b>Current liabilities less total assets</b>		(55,244)	22,873
<b>Provision for liabilities</b>		(17)	-
		(55,261)	22,873
<b>Capital and reserves</b>			
Called up share capital	3	1,000	1,000
Deficit on profit and loss account		(56,261)	21,873
<b>Shareholders' funds</b>		(55,261)	22,873

Continued

The notes on pages 3 to 4 form part of these financial statements

# **Biotech-IgG (UK) Limited**

**Abbreviated balance sheet as at 31st December 2009 (continued)**

**Registered Number 4028374**

---

The abbreviated financial statements are approved in accordance with the special provisions within Part 15 of the Companies Act 2006 relating to small companies

For the financial year ended 31st December 2009 the company was entitled to exemption from audit under section 477 Companies Act 2006 and no notice has been deposited under section 476

The directors acknowledge their responsibility for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of section 396 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements so far as applicable to the company

The financial statements were approved by the board on 24th September 2010 and signed on its behalf by

Dr. M. Krook ..... Director



The notes on pages 3 to 4 form part of these financial statements

# Biotech-IgG (UK) Limited

## Notes to the abbreviated accounts for the year ended 31st December 2009

### 1 Accounting policies

#### a) Accounting convention

The financial statements are prepared under the historical cost basis of accounting and have been prepared in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

The financial statements have been prepared on the going concern basis. The continuation of the company's activities is dependent upon the continuing financial support of the holding company Chemel AB.

#### b) Turnover

Turnover represents the total invoice value, excluding value added tax, of sales during the period.

#### c) Depreciation of tangible fixed assets

Depreciation is provided on all tangible fixed assets at rates calculated to write off the full cost or valuation less estimated residual value of each asset over its estimated useful life. The principal rates in use are:

Plant and equipment	15% reducing balance
---------------------	----------------------

#### d) Deferred taxation

Deferred taxation arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's financial statements. Deferred taxation is provided in full on timing differences which result in obligations to pay more taxation at a future date, at the average taxation rates that are expected to apply when the timing differences reverse, based on current rates and laws.

#### e) Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange prevailing at the accounting date. Transactions in foreign currencies are recorded at the date of the transactions. All differences are taken to the Profit and Loss account.

### 2 Fixed assets

	<i>Tangible fixed assets</i> £
<b>Cost:</b>	
At 1st January 2009 & 31st December 2009	1,200
<b>Depreciation:</b>	
At 1st January 2009	1,104
Provision for the year	14
At 31st December 2009	1,118
<b>Net book value:</b>	
At 31st December 2009	82
At 31st December 2008	96

# Biotech-IgG (UK) Limited

## Notes to the abbreviated accounts for the year ended 31st December 2009 (continued)

---

### 3 Called-up share capital

	<u>2009</u> £	<u>2008</u> £
<i>Allotted, called up and fully paid</i>		
1000 ordinary shares of £1 each	<u>1,000</u>	<u>1,000</u>

### 4 Related parties

#### Controlling entity

The company is wholly owned by Chemel AB, a company incorporated in Sweden (2008 - company owned and controlled by Mr A J Hurst)

The Chemel Group was formed by the acquisition of the assets in Biotech-IgG A/S (DK) including the daughter company Biotech-IgG (UK) Limited and the associated company Raytest Nordic AB. Financial statements for Chemel AB can be obtained from, IDEON Science Park, Scheelevagen 19F 2, 223 70 LUND